Large-scale Microarray Profiling Reveals Four Stages of Immune Escape in Non-Hodgkin Lymphomas

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2016 Sep 14

PMID 27622044

Citations 29

Authors

Marie Tosolini

Christelle Algans

Frederic Pont

Bernard Ycart

Jean-Jacques Fournie

Affiliations

Soon will be listed here.

Abstract

Non-Hodgkin B-cell lymphoma (B-NHL) are aggressive lymphoid malignancies that develop in patients due to oncogenic activation, chemo-resistance, and immune evasion. Tumor biopsies show that B-NHL frequently uses several immune escape strategies, which has hindered the development of checkpoint blockade immunotherapies in these diseases. To gain a better understanding of B-NHL immune editing, we hypothesized that the transcriptional hallmarks of immune escape associated with these diseases could be identified from the meta-analysis of large series of microarrays from B-NHL biopsies. Thus, 1446 transcriptome microarrays from seven types of B-NHL were downloaded and assembled from 33 public Gene Expression Omnibus (GEO) datasets, and a method for scoring the transcriptional hallmarks in single samples was developed. This approach was validated by matching scores to phenotypic hallmarks of B-NHL such as proliferation, signaling, metabolic activity, and leucocyte infiltration. Through this method, we observed a significant enrichment of 33 immune escape genes in most diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) samples, with fewer in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) samples. Comparing these gene expression patterns with overall survival data evidenced four stages of cancer immune editing in B-NHL: non-immunogenic tumors (stage 1), immunogenic tumors without immune escape (stage 2), immunogenic tumors with immune escape (stage 3), and fully immuno-edited tumors (stage 4). This model complements the standard international prognostic indices for B-NHL and proposes that immune escape stages 3 and 4 (76% of the FL and DLBCL samples in this data set) identify patients relevant for checkpoint blockade immunotherapies.

Citing Articles

Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients.

Dufau C, Genais M, Mucher E, Jung B, Garcia V, Montfort A Front Immunol. 2024; 15:1421432.

PMID: 39136013 PMC: 11317267. DOI: 10.3389/fimmu.2024.1421432.

The STEMRI trial: Magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma stem-like cells.

Lemarie A, Lubrano V, Delmas C, Lusque A, Cerapio J, Perrier M Sci Adv. 2023; 9(44):eadi0114.

PMID: 37922359 PMC: 10624352. DOI: 10.1126/sciadv.adi0114.

Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.

Faria C, Gava F, Gravelle P, Valero J, Dobano-Lopez C, Van Acker N J Immunother Cancer. 2023; 11(10).

PMID: 37899130 PMC: 10619028. DOI: 10.1136/jitc-2023-007156.

Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma.

Zhang W, Shi J, Wang H, Zhang T, Zhou X, Zhang H Ann Transl Med. 2023; 10(24):1323.

PMID: 36660618 PMC: 9843426. DOI: 10.21037/atm-22-5815.

CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment.

Lou X, Zhao K, Xu J, Shuai L, Niu H, Cao Z Front Immunol. 2022; 13:950213.

PMID: 36072582 PMC: 9441746. DOI: 10.3389/fimmu.2022.950213.

References

Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L . Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology. 2015; 4(8):e1026530. PMC: 4570141. DOI: 10.1080/2162402X.2015.1026530. View

Schmitz R, Young R, Ceribelli M, Jhavar S, Xiao W, Zhang M . Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418):116-20. PMC: 3609867. DOI: 10.1038/nature11378. View

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View

Tsodikov A, Szabo A, Jones D . Adjustments and measures of differential expression for microarray data. Bioinformatics. 2002; 18(2):251-60. DOI: 10.1093/bioinformatics/18.2.251. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Gundem G, Lopez-Bigas N . Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. Genome Med. 2012; 4(3):28. PMC: 3446278. DOI: 10.1186/gm327. View

Amiot L, Onno M, Lamy T, Dauriac C, Le Prise P, Fauchet R . Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol. 1998; 100(4):655-63. DOI: 10.1046/j.1365-2141.1998.00631.x. View

Wright G, Tan B, Rosenwald A, Hurt E, Wiestner A, Staudt L . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003; 100(17):9991-6. PMC: 187912. DOI: 10.1073/pnas.1732008100. View

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R . Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6):851-62. PMC: 2194208. DOI: 10.1084/jem.20031074. View

10.

Armand P . Checkpoint blockade in lymphoma. Hematology Am Soc Hematol Educ Program. 2015; 2015:69-73. DOI: 10.1182/asheducation-2015.1.69. View

11.

Green M, Kihira S, Liu C, Nair R, Salari R, Gentles A . Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A. 2015; 112(10):E1116-25. PMC: 4364211. DOI: 10.1073/pnas.1501199112. View

12.

Mizuno H, Nakanishi Y, Ishii N, Sarai A, Kitada K . A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics. 2009; 10:137. PMC: 2676301. DOI: 10.1186/1471-2164-10-137. View

13.

Verhaak R, Tamayo P, Yang J, Hubbard D, Zhang H, Creighton C . Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2012; 123(1):517-25. PMC: 3533304. DOI: 10.1172/JCI65833. View

14.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

15.

Harris M, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R . The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2003; 32(Database issue):D258-61. PMC: 308770. DOI: 10.1093/nar/gkh036. View

16.

Kluin-Nelemans H, Beverstock G, Mollevanger P, Wessels H, Hoogendoorn E, Willemze R . Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood. 1994; 84(9):3134-41. View

17.

Isensee J, Witt H, Pregla R, Hetzer R, Regitz-Zagrosek V, Ruiz Noppinger P . Sexually dimorphic gene expression in the heart of mice and men. J Mol Med (Berl). 2007; 86(1):61-74. PMC: 2755745. DOI: 10.1007/s00109-007-0240-z. View

18.

Ycart B, Pont F, Fournie J . Curbing false discovery rates in interpretation of genome-wide expression profiles. J Biomed Inform. 2013; 47:58-61. DOI: 10.1016/j.jbi.2013.09.004. View

19.

Xerri L, Chetaille B, Serriari N, Seriari N, Attias C, Guillaume Y . Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008; 39(7):1050-8. DOI: 10.1016/j.humpath.2007.11.012. View

20.

Xie M, Wu K, Liu Y, Jiang Q, Xie Y . Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2014; 32(1):446. DOI: 10.1007/s12032-014-0446-1. View